All of the above discussed beneficial changes are consistent with the known Nrf2 activation and NF-κB inhibition properties of RTA dh404, which may at least, in part, contribute to the protection associated with RTA dh404 administration in this model of CKD. This evidence concerns the gene NFE2L2 and chronic kidney disease.